Free Kappa light chains in neuroinflammatory disorders: Complement rather than substitute?

2018 ◽  
Vol 138 (4) ◽  
pp. 352-358 ◽  
Author(s):  
J.-L. Bayart ◽  
N. Muls ◽  
V. van Pesch
Keyword(s):  
Light Chains ◽  
Kappa Light Chains

scholarly journals Response to therapy in IgG myeloma patients excreting lambda or kappa light chains: CALGB experience

Blood ◽  
1979 ◽  
Vol 54 (1) ◽  
pp. 23-29 ◽  
Author(s):  
CJ Jr Cornell ◽  
OR McIntyre ◽  
S Kochwa ◽  
BB Weksler ◽  
TF Pajak
Keyword(s):  
Median Survival ◽  
Response To Therapy ◽  
Light Chains ◽  
Urine Protein ◽  
Kappa Light Chains ◽  
Group B ◽  
Leukemia Group ◽  
Bence Jones Proteinuria ◽  
Serum And Urine ◽  
Better Than

Abstract Sixty-eight previously untreated patients with IgG myeloma who were entered into five protocols of Cancer and Leukemia Group B (CALGB) were studied in order to determine the possible influence of excretion of kappa versus lambda urinary light chains on responses to treatment and survival. All patients in these protocols were included if the serum and urine protein abnormalities were confirmed by one of the two group reference laboratories. Pretreatment characteristics of the two groups of patients did not differ significantly. Of 44 patients with kappa Bence Jones proteinuria, 19 patients (43%) had good responses to treatment, whereas only 3 of 24 patients (13%) with lambda Bence Jones proteinuria had good responses (p = 0.02). Survival for the patients excreting kappa light chains was significantly better than survival for patients excreting lambda chains (median survival 31 versus 12 mo, p = 0.02).

scholarly journals Expression of a public idiotype by human monoclonal IgM directed to myelin-associated glycoprotein and characterization of the variability subgroup of their heavy and light chains.

1989 ◽  
Vol 170 (5) ◽  
pp. 1551-1558 ◽  
Author(s):  
J C Brouet ◽  
K Dellagi ◽  
M C Gendron ◽  
A Chevalier ◽  
C Schmitt ◽  
...  
Keyword(s):  
Nonhuman Primate ◽  
Light Chains ◽  
Antibody Activity ◽  
Rheumatoid Factors ◽  
Variable Regions ◽  
Cold Agglutinins ◽  
Heavy Chains ◽  
Myelin Associated Glycoprotein ◽  
Kappa Light Chains

Most studies using rabbit or mouse antisera failed to detect CRI between human IgM directed to MAG. We show here that 9 of 10 such IgM express a public CRI as defined by a nonhuman primate antiserum. Shared idiotype is likely involved in (or close to) the combining site of those IgM since antiidiotypic serum inhibited the binding of IgM to MAG and reacted with IgM having different variable regions of light and heavy chains. Partial aminoterminal sequence of heavy and light chains showed that anti-MAG IgM use either lambda chains (one IgM) or kappa light chains (six IgM) of different variability subgroups (V kappa IV in three instances, V kappa I in two, and V kappa II in one), whereas heavy chains belong to the VHIII (six IgM) or to the VHII (1 IgM) subgroup. These features distinguish these IgM from other human monoclonal IgM with a defined antibody activity, such as rheumatoid factors or cold agglutinins.

scholarly journals Lack of K1b9 light chains in Basilea rabbits is probably due to a mutation in an acceptor site for mRNA splicing.

1985 ◽  
Vol 162 (4) ◽  
pp. 1149-1160 ◽  
Author(s):  
E Lamoyi ◽  
R G Mage
Keyword(s):  
Light Chain ◽  
Splice Site ◽  
Molecular Basis ◽  
Mrna Splicing ◽  
Light Chains ◽  
Acceptor Site ◽  
Acceptor Splice Site ◽  
Normal Gene ◽  
Kappa Light Chains ◽  
Rule Out

Rabbits of the Basilea strain do not produce normal K1b9 light chains but continue to produce immunoglobulins with light chains of the rare K2 isotype and of lambda type. To understand the molecular basis for this unusual expression of kappa light chains in Basilea rabbits, we undertook an analysis of their kappa genes. We isolated and sequenced the mutant kappa 1b9 gene and found a substitution of A for G in the highly conserved AG dinucleotide of the 3' acceptor splice site. Although we cannot rule out additional alterations of portions of the gene we did not sequence, this spontaneous change of the G found in the normal gene provides a likely molecular explanation for the loss of K1 light chain expression in Basilea rabbits.

Evidence of cerebrospinal fluid free kappa light chains in AIDS patients with Toxoplasma gondii encephalitis

2000 ◽  
Vol 108 (1-2) ◽  
pp. 221-226 ◽  
Author(s):  
Carlo Contini ◽  
Enrico Fainardi ◽  
Rosario Cultrera ◽  
Silva Seraceni ◽  
Massimiliano Castellazzi ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Toxoplasma Gondii ◽  
Light Chains ◽  
Aids Patients ◽  
Kappa Light Chains

Cell membrane associated free kappa light chains are found on a subset of tonsil and in vitro-derived plasmablasts

2014 ◽  
Vol 75 (9) ◽  
pp. 986-990 ◽  
Author(s):  
Andrew T. Hutchinson ◽  
Darren R. Jones ◽  
Padraig McCauley Winter ◽  
Stuart G. Tangye ◽  
Robert L. Raison
Keyword(s):  
Cell Membrane ◽  
Light Chains ◽  
Kappa Light Chains

Isolated extramedullary plasmacytoma of the true vocal fold

2000 ◽  
Vol 114 (7) ◽  
pp. 540-542 ◽  
Author(s):  
Yoseph Rakover ◽  
Michael Bennett ◽  
Rephael David ◽  
Gabriel Rosen
Keyword(s):  
Vocal Fold ◽  
Plasma Cells ◽  
Surgical Excision ◽  
Extramedullary Plasmacytoma ◽  
Light Chains ◽  
History Of ◽  
Kappa Light Chains ◽  
One Year ◽  
The Right ◽  
Local Surgical Excision

We report a rare case of isolated extramedullary plasmacytoma (EMP) of the right true vocal fold in a 38-year-old male with a one-year history of hoarseness. Immunohistochemical staining of plasma cells in the tumour, showed over 90 per cent of them to be positive for kappa light chains. After two attempts at local surgical excision and recurrence within 10 months, the tumour was irradiated.Only seven reported cases of isolated EMP of the true vocal fold are reported in the literature. The therapeutic options are discussed.

scholarly journals HHV8/EBV Coinfection Lymphoproliferative Disorder: Rare Entity with a Favorable Outcome

2017 ◽  
Vol 2017 ◽  
pp. 1-8 ◽  
Author(s):  
Dhouha Bacha ◽  
Beya Chelly ◽  
Houda Kilani ◽  
Lamia Charfi ◽  
Amel Douggaz ◽  
...  
Keyword(s):  
Differential Diagnosis ◽  
Lymphoproliferative Disorder ◽  
Clinical Presentation ◽  
B Cell Lymphoma ◽  
Castleman Disease ◽  
Lymphoid Cells ◽  
Light Chains ◽  
Pcr Analysis ◽  
Pathologic Features ◽  
Kappa Light Chains

HHV8/EBV-associated germinotropic lymphoproliferative disorder (GLD) is a challenging diagnosis given its rarity, the particular clinical presentation, and the lack of expression of markers usually used in establishing hematopoietic lineage. We report a new case of HHV8/EBV GLD in an immunocompetent 78-year-old woman. The diagnosis was made in an incidentally discovered lymphadenopathy. Histological examination showed a nodular lymphoid proliferation centered by aggregates of atypical plasmablastic cells admixed with small lymphoid cells. Tumor cells were strongly positive with EMA, HHV8, LMP1, CD38, CD138, and kappa light chains. They were negative with common lymphoma-associated markers (CD20, CD3, CD15, CD30, CD10, and bcl2). In situ hybridization confirmed the monotypic kappa light chains and the EBV infection (EBER+). A polyclonal pattern of Ig gene rearrangement was detected by PCR analysis. In the adjacent lymph node parenchyma, some germinal centers mimicked Castleman disease. In this case, the differential diagnosis was discussed with an early stage of large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease. The clinical presentation, the immunophenotype, and the molecular results helped to make the accurate diagnosis. Through the review of the nine previously reported cases in literature, we discuss the clinical and pathologic features and the differential diagnosis of HHV8/EBV GLD.

Sign in / Sign up

Export Citation Format

Share Document